Humacyte

🚨 Happening Tonight!
Don't miss this exclusive SVS Women's Section educational webinar on AV Access in women.
Hear from:
• Laura E. Niklason, MD, PhD, CEO, Humacyte
• Lisa F. Bennett, MD, Denver, CO
• Young M. Erben, MD, Jacksonville, FL

🚨 Join the SVS Women’s Section for an exclusive educational webinar on AV access in women.

Humacyte will present the complete 12-month interim analysis from the CLN-PRO-V012 study, a multicenter, randomized Phase 3 trial evaluating the acellular tissue-engineered vessel (ATEV) compared with autogenous arteriovenous fistula (AVF) for hemodialysis vascular access in women with end-stage kidney disease.

Women have historically experienced lower rates of AVF maturation, greater catheter dependence, and higher rates of vascular access complications than men—yet prospective randomized studies specifically designed to address this unmet need have been limited. This one-hour webinar will review efficacy and safety outcomes, clinical interpretation of the findings, and potential implications for future vascular access strategies in women at increased risk of AVF maturation failure.

REGISTER NOW: 🔗 https://vascular.org/vascular-specialists/education-and-meetings/meetings/interim-analysis-results-pivotal-randomized

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

🚨 Join the SVS Women’s Section for an exclusive educational webinar on AV access in women.

Humacyte will present the complete 12-month interim analysis from the CLN-PRO-V012 study, a multicenter, randomized Phase 3 trial evaluating the acellular tissue-engineered vessel (ATEV) compared with autogenous arteriovenous fistula (AVF) for hemodialysis vascular access in women with end-stage kidney disease.

Women have historically experienced lower rates of AVF maturation, greater catheter dependence, and higher rates of vascular access complications than men—yet prospective randomized studies specifically designed to address this unmet need have been limited. This one-hour webinar will review efficacy and safety outcomes, clinical interpretation of the findings, and potential implications for future vascular access strategies in women at increased risk of AVF maturation failure.

REGISTER NOW: 🔗 https://vascular.org/vascular-specialists/education-and-meetings/meetings/interim-analysis-results-pivotal-randomized

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

🚨 A significant milestone for the advancement of vascular access care.

Results from Humacyte’s Phase 3 V007 trial have been published in The Lancet Digital Health, providing peer-reviewed validation of positive findings showing the superiority of the ATEV over autogenous arteriovenous fistula (AVF) for hemodialysis vascular access after one year of follow-up. These data demonstrate the potential of the ATEV to help address an important unmet need in hemodialysis access for patients at higher risk of fistula failure, particularly for all female patients and male patients with obesity and diabetes. The publication complements Humacyte’s positive Phase 3 V012 data in women on dialysis, further strengthening the growing body of evidence supporting the investigational use of the ATEV in AV Access.

For more details, read the full press release here: 🔗 https://bit.ly/4wzRZUQ

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an
investigational product and has not been approved for sale by the FDA or any other regulatory
agency.

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

🚨 Symvess® acellular tissue engineered vessel-tyod reaches a new commercial milestone in Arizona.

Humacyte is pleased to announce that Jeromy Brink, MD, a board-certified vascular and endovascular surgeon in Phoenix, performed the first post-BLA approval Symvess implants in Arizona.

This milestone reflects continued market adoption of Symvess as hospitals and surgeons add an important on-demand treatment option for appropriate vascular injury patients.

After gaining access to the first-in-class product, Dr. Brink has already performed four Symvess implants in Phoenix, AZ and described Symvess as the “most revolutionary advancement in open surgical bypass in 30 years.”

Symvess is the first and only FDA-approved bioengineered human vessel and is available off the shelf in the operating room for adults with extremity arterial injury when autologous vein graft is not feasible.

For more details, read the full press release here: 🔗bit.ly/4zq5GrQ

Learn more about Humacyte at www.humacyte.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

A major milestone for Humacyte and the future of cardiovascular care!

The FDA has accepted our IND application for the first-in-human clinical study of the Coronary Tissue Engineered Vessel (CTEV) in coronary artery bypass grafting (CABG). CTEV is a first-in-class, universally implantable bioengineered human blood vessel produced using the same platform as Humacyte's FDA-approved acellular tissue engineered vessel (ATEV) and is designed to be available off-the-shelf, eliminating the need to harvest a patient's own vessel for bypass surgery.

This important regulatory milestone brings us one step closer to evaluating a potential new treatment option for patients undergoing one of the most common cardiovascular procedures performed today.

Phase 2a study initiation is expected this quarter.

For more details read the full press release here: 🔗 https://bit.ly/4x7D6d3

The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

$HUMA

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.